Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer | Pharmacogenomics
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
EGFR signaling in colorectal cancer: a clinical perspective | GICTT
Epidermal growth factor receptor (EGFR)-related signaling pathway in... | Download Scientific Diagram
Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway - ScienceDirect
Y‑box‑binding protein 1 inhibits apoptosis and upregulates EGFR in colon cancer
APMG Colon Molecular Pathways
Les biomarqueurs prédictifs dans le cancer colorectal
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
New combination therapy offers bowel cancer patients extra treatment option
Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives - Annals of Oncology
Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumab - Kim - 2020 - International Journal of Cancer - Wiley Online Library
Biomarkers in Targeted Therapy for Colorectal Cancer
![PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2e5f89dec8a25afc1d61dc3d7197afa33839845d/3-Figure2-1.png "PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar")
PDF] Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar
Biomarqueurs des cancers colorectaux utiles en pratique clinique – FMC-HGE
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. - Abstract - Europe PMC
Cancers | Free Full-Text | Immune Resistance and EGFR Antagonists in Colorectal Cancer
Biomarkers in colorectal cancer: Current clinical utility and future perspectives
Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer | Aging
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer | Oncogene
Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies | Personalized Medicine
Frontiers | The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells | Oncotarget
